Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(04): 211-225
DOI: 10.4103/sajc.sajc_169_19
Letter to the Editor

Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience

Vikas T. Talreja
Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Vanita Noronha
Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Amit Joshi
Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Vijay Patil
Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Abhishek Mahajan
Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Kumar Prabhash
Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
14 December 2020

© 2019. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol 2018;36:2251-8.
  • 2 Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study. Lancet Oncol 2018;19:1654-67. Erratum in: Lancet Oncol 2019;20:e10.